Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06038526 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Canakinumab in High-Risk Former-Smokers
A Phase 2 study of Lung Carcinoma and Cigarette Smoking-Related Carcinoma, sponsored by Peter Shields.
- Active
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT06038526: Active Phase 2 study of Lung Carcinoma and Cigarette Smoking-Related Carcinoma, sponsored by Peter Shields.
NCT06038526 is a Phase 2 study of Lung Carcinoma and Cigarette Smoking-Related Carcinoma that is active but no longer recruiting, run by Peter Shields. The registered enrollment target is 41 participants, below the 5,043-participant average among 38 other Lung Carcinoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06038526, a Phase 2 study of Lung Carcinoma and Cigarette Smoking-Related Carcinoma, is active but no longer recruiting, sponsored by Peter Shields.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests the impact of canakinumab on biologic samples (buccal, nasal, and blood) from former smokers with increased risk of cancer. Canakinumab blocks the activity of a protein called interleukin-1 beta (IL-1b), an agent of the inflammatory system and is used for the treatment of different non-cancer diseases (like auto-inflammatory diseases). Giving canakinumab may block the inflammatory system and could have positive effects to reduce cancer growth.
Primary Outcome
Will be assessed by a generalized linear mixed model (GLM) and will be employed with measure as the dependent variable, a main effect of baseline vs. follow-up, covariables sex and age, and a random effect for subject.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Survey Administration
- PROCEDURE Bronchoscopy
- PROCEDURE Carbon Monoxide Measurement
- BIOLOGICAL Canakinumab
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2024-03-11 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
What the registry record for NCT06038526 still lists
NCT06038526 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 5,043-participant average among 38 other Lung Carcinoma trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Lung Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06038526 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06038526 about?
NCT06038526 is a clinical study titled "Evaluation of Canakinumab in High-Risk Former-Smokers". This phase II trial tests the impact of canakinumab on biologic samples (buccal, nasal, and blood) from former smokers with increased risk of cancer. Canakinumab blocks the activity of a protein called interleukin-1 beta (IL-1b), an agent of the inflammatory system and is used for the treatment of d...
What is the current status of trial NCT06038526?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2024-03-11. Estimated completion is 2026-07-31.
What conditions does trial NCT06038526 study?
This clinical trial studies the following conditions: Lung Carcinoma, Cigarette Smoking-Related Carcinoma.
What interventions are being tested in trial NCT06038526?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Survey Administration (OTHER), Bronchoscopy (PROCEDURE), Carbon Monoxide Measurement (PROCEDURE), Canakinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06038526?
This trial is sponsored by Peter Shields, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06038526 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06038526's enrollment target sits among peer trials
41 29th of 38 higher than 10 of 38 other Lung Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
RECRUITING · Phase 2
-
Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
The Rise in Robotic Atypical Segmentectomies
RECRUITING
-
Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (Interception for Suspected Lung Cancer)
RECRUITING
-
Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI